# Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

> **NCT00638690** · PHASE3 · COMPLETED · sponsor: **Cougar Biotechnology, Inc.** · enrollment: 1195 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Placebo
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone/prednisolone

## Key facts

- **NCT ID:** NCT00638690
- **Lead sponsor:** Cougar Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-08
- **Final completion:** 2012-10
- **Target enrollment:** 1195 (ACTUAL)
- **Last updated:** 2014-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00638690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00638690, "Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00638690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*